Stomach signet ring cell carcinoma tissue preserving fluid, digestive juice and special culture system of organoid

By designing a dedicated gastric mark ring cell carcinoma tissue transport preservation fluid, digestive fluid and organoid culture medium, combined with broad-spectrum antibiotics and ROS antagonists, the problem of low success rate of tissue culture of gastric mark ring cell carcinoma in traditional technology is solved, and the problem of low success rate of tissue culture of gastric mark ring cell carcinoma in traditional technology is achieved. It has higher cell activity and lower risk of contamination, significantly improving the success rate of organoid culture of gastric mark ring cell carcinoma.

CN118923665APending Publication Date: 2024-11-12THE FIRST HOSPITAL OF CHINA MEDICIAL UNIV
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411141979.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Traditional tissue transport, digestion and organoid culture medium cannot effectively maintain the high activity of gastric mark ring cell carcinoma tissue and avoid cell culture contamination, resulting in a low culture success rate.

Method used

A special culture system including gastric mark ring cell carcinoma tissue transport preservative fluid, digestive fluid and organoid complete medium was designed, using DMEM culture medium, serum, CEPT small molecule mixture, NAC, primocin, collagenase and dispersase, etc. Ingredients, combined with broad-spectrum antibiotics and ROS antagonists, ensure tissue stability and digestive efficiency during transport and digestion, and improve cell survival and growth through specific medium combinations.

Benefits of technology

It significantly improved the success rate of the culture of organoids of gastric mark ring cell carcinoma, shortened the operation time and digestion time of specimens to the laboratory, reduced the risk of contamination, and improved cell viability and culture efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118923665A_ABST
    Figure CN118923665A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of cell engineering, in particular to a gastric signet ring cell carcinoma tissue preserving fluid, digestive juice and a special culture system of organoids. The method disclosed by the invention relates to the whole process from elm to culture of a gastric signet-ring cell carcinoma specimen, and specifically designs a gastric signet-ring cell carcinoma tissue transport preserving fluid, a tissue digestive juice and an organoid complete culture medium based on the characteristics of gastric signet-ring cell carcinoma tissue. The whole culture system has high specificity and higher success rate for the primary culture of the organoids derived from the gastric signet ring cell carcinoma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell engineering technology, and in particular to a special culture system of a gastric signet ring cell carcinoma tissue preservation fluid, a digestive fluid and an organoid. Background Art

[0002] Signet ring cell carcinoma is a special type of gastric cancer, characterized by cell mucus secretion. Compared with other histological types of gastric cancer, signet ring cell carcinoma mostly shows diffuse invasive growth, is more common in young women, has strong invasiveness and poor prognosis. Gastric signet ring cell carcinoma has its own particularities in ultrastructure, pathological manifestations, functional differentiation phenotypes, and other related tumor molecular biology. The use of traditional tissue transportation, tissue digestion, and organoid culture medium, the problem of contamination in cell culture due to tissue-carrying bacteria, and the high activity of the tissue after ex vivo cannot be guaranteed, which seriously affects the cell activity of gastric signet ring cell carcinoma specimens and the success rate of primary culture. Therefore, it is urgent to establish a complete set of gastric signet ring cell carcinoma-derived organoid primary culture system from transportation to culture for gastric signet ring cell carcinoma. Summary of the invention

[0003] In view of the problems existing in the prior art, the purpose of the present invention is to provide a tissue preservation solution for a special gastric cancer classification - gastric signet ring cell carcinoma, as well as a special culture system for tissue transportation, tissue digestion and organoid culture of optimal gastric signet ring cell carcinoma organoids.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions.

[0005] The present invention discloses a transport and preservation solution for gastric signet ring cell carcinoma tissue, characterized in that the transport and preservation solution comprises the following components: DMEM culture medium, serum, CEPT small molecule mixture, NAC, primocin, collagenase Ⅺ and dispase; The total volume of the transport preservation solution includes: 1×DMEM culture medium, 2.5% serum, 1×CEPT small molecule mixture, 1.25 mM NAC, 1000×primocin, 80 U / mL collagenase Ⅺ and 125 ug / mL dispase.

[0006] The present invention also discloses a digestive fluid of gastric signet ring cell carcinoma tissue, characterized in that the digestive fluid comprises the following components: Advanced DMEM / F12 culture medium, serum, CEPT small molecule mixture, NAC, primocin, collagenase Ⅺ, dispase, hyaluronidase and papain; The total volume of the digestion solution includes: 1×Advanced DMEM / F12 culture medium, 2.5% serum, 1×CEPT small molecule mixture, 1.25 mM NAC, 1000×primocin, 80 U / mL collagenase XI, 125 ug / mL dispase, 20 ug / mL hyaluronidase and 0.5 mg / mL papain.

[0007] The present invention also discloses a complete culture medium for gastric signet ring cell carcinoma tissue organoids, characterized in that the culture medium comprises the following components: Advanced DMEM / F12 culture medium, GlutaMax, CEPT small molecule mixture, NAC, primocin, HEPES, FGF-10, EGF, R-Spondin 1, Noggin, Wnt-3a, A83-01, Gastrin, SB202190, Insulin, VEGF, PGE2, FGF-2, B27, N2 and Nicotinamide; The total volume of the culture medium includes: 1×Advanced DMEM / F12 medium, 100×GlutaMax, 1×CEPT small molecule mixture, 1.25mM NAC, 1000×primocin, 10mM HEPES, 200ng / mL FGF-10, 50ng / mL EGF, 1ug / mL R-Spondin 1, 100ng / mL Noggin, 100ng / mL Wnt-3a, 500nM A83-01, 10nM Gastrin, 500nM SB202190, 50ng / mL Insulin, 100ng / mL VEGF, 1μM PGE2, 1ng / mL FGF-2, 50×B27, 100×N2 and 10mM Nicotinamide.

[0008] The present invention also discloses a method for culturing gastric signet ring cell carcinoma tissue organoids, which is characterized by comprising: culturing gastric signet ring cell carcinoma tissue cells in any one of the above-mentioned transport preservation fluid, digestive fluid and culture medium to obtain the gastric signet ring cell carcinoma tissue organoids.

[0009] Furthermore, the specific steps include the following steps: Step 1 Transportation and preservation of gastric signet ring cell carcinoma tissue: After taking the gastric signet ring cell carcinoma tissue, put it into the pre-cooled gastric signet ring cell carcinoma tissue transportation preservation solution as soon as possible (within 10 minutes of ex vivo), and the gastric signet ring cell carcinoma tumor tissue should be completely covered by the tissue transportation preservation solution; transport it to the laboratory at a constant temperature of 4°C; Step 2 Digestion of gastric signet ring cell carcinoma tissue: The gastric signet ring cell carcinoma tissue was removed in a clean bench and rinsed three times with pre-cooled PBS buffer containing antibiotics; the rinsed gastric tumor tissue was mechanically dissociated into 1 mm2 pieces using a surgical blade and ophthalmic scissors. 3 Add gastric signet ring cell carcinoma tissue digestion solution preheated at 37°C to the tissue blocks of different sizes and digest them in a shaking water bath at 37°C for 30-45 minutes. Step 3: Culture of gastric signet ring cell carcinoma organoids: After digestion of gastric signet ring cell carcinoma tumor tissue, add an equal volume of stop solution to stop digestion, pipette 100 times, and let stand on ice for 10 minutes; remove extracellular matrix impurities through a 70μm sieve and centrifuge; discard the supernatant and collect the supernatant; add an appropriate amount of 3D matrix gel to the single-cell pellet and gently resuspend the cells to avoid bubbles, and add the matrix gel-cell mixture to a 24-well plate at 50µL / well; incubate at 37℃ for 10 minutes; after the matrix gel solidifies, add 500µL / well of culture medium (preheated at 37℃ in advance); replace the growth medium every three days, and the growth cycle of each generation of gastric tumor organoids is approximately 7-14 days.

[0010] The present invention also discloses a method for constructing a gastric signet ring cell carcinoma organoid bank, which is characterized in that it comprises: obtaining gastric signet ring cell carcinoma tissue organoids according to any of the above methods, subculturing the gastric signet ring cell carcinoma organoids to obtain subcultured gastric signet ring cell carcinoma organoids, and freezing the subcultured gastric signet ring cell carcinoma organoids to obtain the gastric signet ring cell carcinoma organoid bank.

[0011] The present invention also discloses a kit, which contains any one of the above-mentioned transport and preservation solutions, digestion solutions and culture media.

[0012] The present invention also discloses an application of the above-mentioned kit in culturing gastric signet ring cell carcinoma organoids.

[0013] The present invention also discloses a cell culture, characterized in that the cell culture contains any one of the above-mentioned transport preservation solution, digestion solution and culture medium and gastric signet ring cell carcinoma tissue / gastric signet ring cell cancer cells.

[0014] Furthermore, the cell culture is used in culturing gastric signet ring cell carcinoma organoids.

[0015] Compared with the prior art, the beneficial effects of the present invention are as follows.

[0016] 1. Based on the characteristics of gastric signet ring cell carcinoma tissue, the present invention specifically designs gastric signet ring cell carcinoma tissue transport preservation fluid, tissue digestion fluid, and organoid complete culture medium. The entire culture system is highly specific for the primary culture of organoids derived from gastric signet ring cell carcinoma and has a higher success rate.

[0017] 2. Compared with traditional tissue preservation fluid, the present invention specifically adds a strong digestive enzyme for gastric signet ring cell carcinoma in the tissue transport preservation fluid, which ensures that the tissue is slowly digested during transportation. Compared with traditional tissue transport preservation fluid, the operation time and digestion time after the specimen arrives at the laboratory can be shortened by 0.5~1h, and the success rate of organoids can be increased by about 10~20%.

[0018] 3. Compared with traditional tissue preservation fluid, the present invention adds powerful broad-spectrum antibiotics to the tissue transport preservation fluid, which can prevent the infection of tumor tissue by the resident flora of the digestive tract, thereby avoiding contamination of primary culture of organoids.

[0019] 4. Compared with traditional tissue digestion fluid, the present invention specifically adds ROS antagonist (NAC) to avoid peroxidation damage of tumor cells caused by ROS accumulation, thereby improving cell viability. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A diagram of gastric signet ring cell carcinoma organoids constructed by the primary culture system of gastric signet ring cell carcinoma-derived organoids of the present invention.

[0021] Figure 2 Tissue preservation fluid containing signet ring cell carcinoma specimens.

[0022] Figure 3 Comparison of the effects of different tissue preservation solutions for gastric signet ring cell carcinoma organoid culture. Figures A, B, and C are respectively the organoid culture diagrams of gastric signet ring cell carcinoma tissues preserved and transported without tissue preservation solution, commercialized tissue preservation solution, and the tissue preservation solution of the present invention; D is a statistical diagram of the size of gastric signet ring cell carcinoma organoids in different tissue preservation solutions; E is a statistical diagram of the number of gastric signet ring cell carcinoma organoids in different tissue preservation solutions.

[0023] Figure 4 Comparison of the viability of signet ring cell carcinoma cells in different digestive solutions.

[0024] Figure 5 Comparison of the effects of different culture media for gastric signet ring cell carcinoma organoid culture. Figure A shows the culture of gastric signet ring cell carcinoma organoid culture media in the present invention; Figure B shows the culture of gastric cancer organoid culture media in traditional culture media. DETAILED DESCRIPTION

[0025] The present invention is further described in detail below with specific embodiments, but it should not be understood that the scope of the above subject matter of the present invention is limited to the following embodiments, and all technologies realized based on the content of the present invention belong to the scope of the present invention.

[0026] Unless otherwise specified, all reagents and materials used in the present invention are commercially available.

[0027] Example 1. Primary culture system of organoids derived from gastric signet ring cell carcinoma (eg Figure 1 as shown).

[0028] Based on the characteristics of gastric signet ring cell carcinoma tissue, the present invention specifically designs a primary culture system of organoids derived from gastric signet ring cell carcinoma. The culture system includes tissue transport preservation fluid, tissue digestion fluid, organoid complete culture medium and specific operation steps of each process involved in the whole process from transportation to culture.

[0029] 1. Transportation and preservation of gastric signet ring cell carcinoma tissue.

[0030] 1. Preparation of gastric signet ring cell carcinoma tissue preservation solution.

[0031] Gastric signet ring cell carcinoma has more intercellular matrix components, so it requires a stronger digestive system and longer digestion time than general tumor tissues. Therefore, digestion during transportation can reduce the time of specimen separation and total digestion, increase cell activity, and increase the success rate of primary culture. In the human body, the stomach is a hollow organ connected to the outside world. The rich blood supply in the gastric tissue and the hydrogen ion-mucus barrier system unique to the gastric mucosa can ensure that the gastric mucosa is not infected by the resident bacteria in the digestive tract. Once separated from the body, bacteria will quickly contaminate the gastric mucosal samples in the absence of broad-spectrum antibiotics, causing the failure of primary culture. Therefore, it is necessary to digest the samples during transportation, digestion, and culture. Broad-spectrum antibiotics are added throughout the process; when tumor tissue is digested in the digestive fluid in vitro, tumor cells cannot perform sufficient aerobic respiration, which will lead to the gradual accumulation of ROS, causing cell peroxidation damage, and then reducing cell viability. Therefore, it is necessary to add ROS antagonists such as NAC throughout the transportation, digestion, and culture process; the anti-oxidative apoptosis ROCK inhibitor Y-27632 is mainly used in general commercial preservation fluids to maintain cell activity and inhibit cell death. The CEPT small molecule mixture used in the present invention (containing 4 small molecule reagents that are beneficial to maintaining cell activity, with specific components and concentrations of: 50 nM Chroman 1 (ROCK2 inhibitor), 5 mM Emricasan (inhibiting cell apoptosis), 1X polyamine supplement (promoting cell growth and survival), 0.7 mM TransISRIB (inhibiting integrated stress response) enhances experimental repeatability, improves cell survival rate, is more conducive to the growth of signet ring cell carcinoma organoids, and improves the culture success rate.

[0032] In summary, in order to solve the problems of low viability of gastric signet ring cell carcinoma tissue specimens during transportation and easy culture contamination caused by bacteria in the tissue, the present invention first provides a tissue preservation fluid that is used to maintain the activity of signet ring cell carcinoma tumor tissue during transportation and has a certain digestive function. The culture medium components are shown in the following table.

[0033] Table 1 Composition of gastric signet ring cell carcinoma tissue transport and preservation solution .

[0034] 2. Specific steps for transportation and preservation of gastric signet ring cell carcinoma tissue.

[0035] After the preparation of gastric signet ring cell carcinoma tissue transport preservation solution is completed, it is dispensed into 15mL centrifuge tubes or 50mL centrifuge tubes at 8mL / tube, stored at -20℃, and thawed at 4℃ overnight before use to avoid repeated freezing and thawing.

[0036] After obtaining the gastric signet ring cell carcinoma tissue, place it in the pre-cooled gastric signet ring cell carcinoma tissue transport preservation solution as soon as possible (within 10 minutes of ex vivo), and the gastric signet ring cell carcinoma tumor tissue should be completely covered by the tissue transport preservation solution. Transport it to the laboratory at a constant temperature of 4°C. Record the transportation process, including but not limited to the transportation method, temperature during transportation, temperature or temperature range at the time of receipt, and transportation start and end time and date. At the end of storage or transportation, remove the signet ring cell carcinoma tissue from the tissue transport preservation solution for gastric signet ring cell carcinoma organoid culture.

[0037] 2. Digestion of gastric signet ring cell carcinoma tissue.

[0038] 1. Preparation of digestive fluid of gastric signet ring cell carcinoma tissue.

[0039] In order to solve the problems of low digestion efficiency of gastric signet ring cell carcinoma tissue, low cell activity, low success rate of organoid culture, etc., the present invention also provides a digestive fluid specifically used for digestion of gastric signet ring cell carcinoma tissue. The components of the gastric signet ring cell carcinoma tissue digestive fluid are shown in the following table.

[0040] Table 2 Composition of digestive fluid from gastric signet ring cell carcinoma .

[0041] 2. Procedures for digestion of gastric signet ring cell carcinoma tissue.

[0042] A mung bean-sized tumor tissue requires 5 mL of digestive solution. The digestive solution should be prepared on the spot and preheated in a 37°C water bath after preparation to allow the digestive enzymes of each component to exert optimal enzymatic activity.

[0043] The gastric signet ring cell carcinoma tissue was removed in a clean bench and rinsed three times with pre-cooled PBS buffer containing antibiotics (manually shaken 100 mm in the clean bench). 2 The rinsed gastric tumor tissue was mechanically dissociated into 1 mm pieces using a surgical blade and ophthalmic scissors. 3 Add gastric signet ring cell carcinoma tissue digestion solution preheated at 37°C to the tissue blocks of different sizes and digest them in a 37°C shaking water bath for 30-45 minutes.

[0044] 3. Gastric signet ring cell carcinoma organoid culture system.

[0045] 1. Complete medium for gastric signet ring cell carcinoma organoid culture system.

[0046] In order to improve the success rate of gastric signet ring cell carcinoma organoid culture and improve the growth state of organoids, the applicant of the present invention has established a culture medium specifically for gastric signet ring cell carcinoma organoid model after extensive research. The components of the culture medium are shown in the following table.

[0047] Table 3 Composition of complete culture medium for gastric signet ring cell carcinoma organoids .

[0048] 2. Specific operation steps of gastric signet ring cell carcinoma organoid culture system.

[0049] After digestion, add an equal volume of stop solution (a mixture containing 10% serum, antibiotics, NAC, Y27632, HEPES, and glutamine) to stop digestion of gastric signet ring cell carcinoma tissue, pipette 100 times, and let stand on ice for 10 minutes. Remove extracellular matrix impurities through a 70μm mesh and centrifuge (4℃, 300×g, 5min). Discard the supernatant, collect the single cell pellet, discard the supernatant into a designated container, and centrally carry out biological harmless treatment. Add an appropriate amount of 3D matrix gel to the single cell pellet (10,000 cells should be inoculated in 50μL matrix gel) to gently resuspend the cells, avoid bubbles, and add the matrix gel-cell mixture to the 24-well plate at 50μL / well. Place in a 37℃ incubator for 10 minutes. After the matrix gel solidifies, supplement the culture medium (Table 3) 500μL / well (preheated at 37℃ in advance). The growth medium was replaced every three days, and the growth cycle of each generation of gastric tumor organoids was approximately 7-14 days.

[0050] Example 2: Effects of different tissue transport and preservation solutions, tissue digestion solutions, and complete culture medium on the effects of gastric signet ring cell carcinoma organoids in the entire culture system.

[0051] 1. Comparison of the effects of the tissue transport preservation solution of the present invention and traditional tissue transport preservation solution.

[0052] A gastric signet ring cell carcinoma organoid culture system was constructed according to the method described in Example 1, except that the transport and preservation solution used was a traditional tissue transport and preservation solution (manufacturer: Bozhen Biotechnology, catalog number: K601005).

[0053] The experimental results are as follows Figure 2~3 As shown, the improved tissue preservation solution of the present invention has the advantages of high cell activity, low contamination rate, high success rate of gastric signet ring cell carcinoma organoid culture, etc.

[0054] 2. Comparison of the effects of the tissue digestion fluid of the present invention and traditional tissue digestion fluid.

[0055] A gastric signet ring cell carcinoma organoid culture system was constructed according to the method described in Example 1, except that the tissue digestion fluid used was a traditional tissue digestion fluid (manufacturer: Yisheng Biotechnology, catalog number: 41423ES10).

[0056] The experimental results are as follows Figure 4 As shown, compared with traditional tissue digestion fluid, the improved digestion fluid of the present invention can better maintain the high activity of gastric signet ring cell carcinoma tumor cells, tissue digestion is more complete and thorough, the tissue digestion time is relatively reduced by 0.5~1h, and the success rate of organoids is increased by 10~20%.

[0057] 3. Comparison of the effects of the gastric signet ring cell carcinoma organoid culture medium of the present invention and the traditional gastric cell carcinoma organoid culture medium.

[0058] A gastric signet ring cell carcinoma organoid culture system was constructed according to the method described in Example 1, except that the gastric signet ring cell carcinoma organoid culture medium used a traditional gastric cell carcinoma organoid culture medium (manufacturer: Yisheng Biotechnology, catalog number: 41428ES50).

[0059] The experimental results are as follows Figure 5 As shown, compared with the traditional gastric cell carcinoma organoid culture medium, the improved gastric signet ring cell carcinoma organoid culture medium specifically for gastric signet ring cell carcinoma has a higher success rate in culturing gastric signet ring cell carcinoma organoids (more organoids) and better cell growth (larger organoid volume).

[0060] The present invention breaks the ratio mode of traditional preservation solution, and specially adds CEPT small molecule mixture (containing 4 small molecule reagents that are beneficial to maintaining cell activity, which enhances the repeatability of the experiment, improves the cell survival rate, and is more conducive to the growth of signet ring cell carcinoma organoids, and improves the success rate of culture. At the same time, the present invention specifically adds potent antibiotics of primary culture to the resident flora in gastric tissue, ensuring tissue activity while reducing the probability of cell culture contamination. At the same time, different types of collagenase combinations are used to ensure slow and strong tissue digestion during tissue transportation, shorten the digestion time of the entire culture system, improve the success rate of organoid culture, and reduce the cell contamination rate.

[0061] The above description is only a preferred embodiment of the present invention and is not intended to limit the scope of the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A gastric signet ring cell carcinoma tissue transport and preservation solution, characterized in that: The components of the transport and preservation solution include: DMEM culture medium, serum, CEPT small molecule mixture, NAC, primocin, collagenase Ⅺ and dispase; The total volume of the transport preservation solution includes: 1×DMEM culture medium, 2.5% serum, 1×CEPT small molecule mixture, 1.25 mM NAC, 1000×primocin, 80 U / mL collagenase Ⅺ and 125 ug / mL dispase.

2. A digestive fluid of gastric signet ring cell carcinoma tissue, characterized in that: The digestion solution comprises: Advanced DMEM / F12 culture medium, serum, CEPT small molecule mixture, NAC, primocin, collagenase Ⅺ, dispase, hyaluronidase and papain; The total volume of the digestion solution includes: 1×Advanced DMEM / F12 culture medium, 2.5% serum, 1×CEPT small molecule mixture, 1.25 mM NAC, 1000Xprimocin, 80 U / mL collagenase XI, 125 ug / mL dispase, 20 ug / mL hyaluronidase and 0.5 mg / mL papain.

3. A complete culture medium for gastric signet ring cell carcinoma tissue organoids, characterized in that: The components of the culture medium include: Advanced DMEM / F12 culture medium, GlutaMax, CEPT small molecule mixture, NAC, primocin, HEPES, FGF-10, EGF, R-Spondin 1, Noggin, Wnt-3a, A83-01, Gastrin, SB202190, Insulin, VEGF, PGE2, FGF-2, B27, N2 and Nicotinamide; The total volume of the culture medium includes: 1×Advanced DMEM / F12 medium, 100×GlutaMax, 1×CEPT small molecule mixture, 1.25mM NAC, 1000×primocin, 10mM HEPES, 200ng / mL FGF-10, 50ng / mL EGF, 1ug / mL R-Spondin 1, 100ng / mL Noggin, 100ng / mL Wnt-3a, 500nM A83-01, 10nM Gastrin, 500nM SB202190, 50ng / mL Insulin, 100ng / mL VEGF, 1μM PGE2, 1ng / mL FGF-2, 50×B27, 100×N2 and 10mM Nicotinamide.

4. A method for culturing gastric signet ring cell carcinoma tissue organoids, characterized in that: include: The gastric signet ring cell carcinoma tissue cells are cultured in the transport storage solution, digestion solution and culture medium described in any one of claims 1 to 3 to obtain the gastric signet ring cell carcinoma tissue organoid.

5. A method for culturing gastric signet ring cell carcinoma tissue organoids according to claim 4, characterized in that: The specific steps include the following steps: Step 1 Transportation and preservation of gastric signet ring cell carcinoma tissue: After taking the gastric signet ring cell carcinoma tissue, put it into the pre-cooled gastric signet ring cell carcinoma tissue transportation preservation solution as soon as possible (within 10 minutes of ex vivo), and the gastric signet ring cell carcinoma tumor tissue should be completely covered by the tissue transportation preservation solution; transport it to the laboratory at a constant temperature of 4°C; Step 2 Digestion of gastric signet ring cell carcinoma tissue: The gastric signet ring cell carcinoma tissue was removed in a clean bench and rinsed three times with pre-cooled PBS buffer containing antibiotics; the rinsed gastric tumor tissue was mechanically dissociated into 1 mm2 pieces using a surgical blade and ophthalmic scissors. 3 Add gastric signet ring cell carcinoma tissue digestion solution preheated at 37°C to the tissue blocks of different sizes and digest them in a shaking water bath at 37°C for 30-45 minutes. Step 3: Culture of gastric signet ring cell carcinoma organoids: After digestion of gastric signet ring cell carcinoma tumor tissue, add an equal volume of stop solution to stop digestion, pipette 100 times, and let stand on ice for 10 minutes; remove extracellular matrix impurities through a 70μm sieve and centrifuge; discard the supernatant and collect the supernatant; add an appropriate amount of 3D matrix gel to the single-cell pellet and gently resuspend the cells to avoid bubbles, and add the matrix gel-cell mixture to a 24-well plate at 50µL / well; incubate at 37℃ for 10 minutes; after the matrix gel solidifies, add 500µL / well of culture medium (preheated at 37℃ in advance); replace the growth medium every three days, and the growth cycle of each generation of gastric tumor organoids is approximately 7-14 days.

6. A method for constructing a gastric signet ring cell carcinoma organoid bank, characterized in that: include: According to the method according to any one of claims 4 to 5, gastric signet ring cell carcinoma tissue organoids are obtained, the gastric signet ring cell carcinoma organoids are subcultured to obtain subcultured gastric signet ring cell carcinoma organoids, and the subcultured gastric signet ring cell carcinoma organoids are cryopreserved to obtain the gastric signet ring cell carcinoma organoid bank.

7. A kit comprising the transport storage solution, digestion solution and culture medium according to any one of claims 1 to 3.

8. Use of the kit according to claim 7 in culturing gastric signet ring cell carcinoma organoids.

9. A cell culture, characterized in that The cell culture contains the transport storage solution, digestion solution and culture medium according to any one of claims 1 to 3 and gastric signet ring cell carcinoma tissue / gastric signet ring cell carcinoma cells.

10. Use of the cell culture according to claim 9 in culturing gastric signet ring cell carcinoma organoids.

Citation Information

Cited By

  • Tissue digestive juice for organoid culture as well as preparation method and application of tissue digestive juice

    CN119320742A

  • Application of sunitinib malate in preparation of targeted therapeutic drug for gastric signet ring cell carcinoma

    CN122140706A